The Food and Drug Administration proposed last month to make testosterone available for age-related symptoms such as low libido and erectile dysfunction, while the current label limits approval to abnormally low levels caused by medical conditions or injury [1]; a proposed rewrite is not a final label or prescribing outcome.

The paper's July 15 account of an Alzheimer's blood-test risk flag kept screening, diagnosis and actionability separate; broader testosterone access must keep symptoms, two tests, benefits and harms distinct.

Endocrine Society guidance calls for documented symptoms and two blood tests confirming low hormone levels, while one recent study found only 12% of men receiving prescriptions met that standard [1]; normal aging alone is not automatically hypogonadism.

The evidence is narrower than vitality marketing: a 5,000-man trial found no increase in major heart events over two years, while studies of nearly 800 older men found improvements in sexual measures but little or none in fatigue, memory or overall well-being [1]; two years cannot settle prostate and other risks that may take decades to emerge, and external testosterone can suppress sperm production and compromise fertility.

The military announced screening on Tuesday, July 14, rather than producing a July 16 program outcome [1], and no auditable same-day X post was recovered, leaving general-vitality and categorical-rejection feed counterframes unobserved; the useful record is proposal, diagnosis, bounded benefit and unresolved harm rather than an all-purpose elixir or a universal rejection.

-- NORA WHITFIELD, Chicago